Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'
August 9, 2022 4:02 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "While we await a seminal decision on pegcetacoplan in GA (11/26/22), APLS continues to execute on the Empaveli/PNH commercial launch, with sales reaching $16.3mn/Cons.... More
Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'
August 9, 2022 4:01 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We continue to view the acceptance, granting of Priority Review for the sNDA for pegcetacoplan in GA and the fact that the... More
Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PT
August 9, 2022 3:58 AM EDTRoth Capital analyst Elemer Piros reiterated a Sell rating and $40.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We arrive at our 12-month price target of $40/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from pegcetacoplan for treatment PNH... More
